高危子宫内膜癌术后辅助同步放化疗与单纯放疗的临床对比
Comparative Study of Concurrent Chemoradiotherapy with Simplex Radiotherapy after Radical Surgery for High-risk Endometrial Cancer
-
摘要: [摘要]目的 对比研究顺铂联合五氟尿嘧啶(PF方案)同步放化疗与单纯放疗辅助治疗术后高危子宫内膜癌的毒性反应和复发,发现盆腔或远处转移病灶.方法 选择2011年10月至2013年6月云南省肿瘤医院初治、接受规范分期手术,有高危因素的子宫内膜癌患者43例为研究对象,22例行单纯放射治疗,21例行术后辅助DDP+5-FU同步放化疗治疗,对比2组的毒性反应和复发率.结果 同步放化疗组与单纯放疗组3极胃肠道反应率分别为61.90%和31.82%(P<0.05 ),差异有统计学意义;2组2级以上骨髓抑制率分别为66.67%和18.18 %(P<0.01 ),差异有统计学意义;2组2级以上周围神经毒性反应率分别为33.33%和13.64%(P>0.05 ) .同步放化疗组与单纯放疗组总体复发率分别为4.76%和27.27%(P<0.05 ),差异有统计学意义.结论 同步放化疗3级胃肠道反应率增加,2级以上骨髓抑制率显著增加,周围神经毒性反应率不增加,毒性反应可以耐受,减少2 a总体复发率.
-
关键词:
- [关键词]子宫内膜癌 /
- 同步放化疗 /
- 放射治疗
Abstract: [Abstract]Objective To compare the toxicities and recurrence rate with concomitant chemoradiotherapy(CRT) and radiotherapy(RT) alone after radical surgery for high-risk endometrial cancer. Methods A total of 43 patients with high-risk endometrial cancer who received standard surgery treatment from Yunnan Cancer Hospital between Oct. 2011 to Jun. 2014 were selected in this study. CRT was given to 21 patients and RT was given to 22 patients. The toxic reactions and the recurrence rate were compared between two groups. Results In Concurrent chemotherapy and radiotherapy alone group, the incidence of Grade 3 gastrointestinal reaction was 61.90% and 31.82% respectively,the difference was statistically significant(P <0.05); the incidence of Grade 2 marrow suppression was 66.67% and 18.18% respectively,the difference was significant(P <0.01);the incidence of Grade 2 neurotoxicity was 33.33% and 13.64%,respectively(P > 0.05);the overall recurrence rate was 4.76% and 27.27%, respectively (P <0.05). Conclusion Compared with the simple radiotherapy,after the concurrent chemoradiotherapy, the incidence of Grade 3 gastrointestinal reaction may increase,the incidence of Grade 2 Bone marrow suppression may also increase significantly,while the incidence of peripheral neurotoxicity may not increase,the toxicity is acceptable, and the 2-year recurrence rate may decrease. 期刊类型引用(7)
1. 王哲哲,祁晓莉,武迪,杜睿,张立英,卢晓红,杜少静. 非小细胞肺癌EGFR和KRAS基因突变和临床病理特征分析. 临床和实验医学杂志. 2022(04): 360-364 . 百度学术
2. 李静,张宁. 非小细胞肺癌患者小分子靶向药物临床使用分析. 深圳中西医结合杂志. 2022(02): 132-134 . 百度学术
3. 苏国苗,王娟,李振辉,潘国庆,李彦熙,刘士岳,曾定涛,杨哲,雷梓. 云南地区非小细胞肺癌10种驱动基因突变联合检测分析. 分子诊断与治疗杂志. 2022(08): 1292-1295+1299 . 百度学术
4. 谭显海,董陶明,计菲燕. RDS预测NSCLC患者放化疗疗效的临床观察研究. 江西医药. 2022(07): 714-716 . 百度学术
5. 韦礼肥,黄林达,陆相磊,杨洁,王兴枝子,龙喜带,朱晓莹. 桂西地区壮族非小细胞肺癌患者EGFR基因突变与临床病理特征的相关性分析. 检验医学与临床. 2022(19): 2635-2638 . 百度学术
6. 钟炜祥,韦晰凤. 赣南地区非小细胞肺癌EGFR突变和ALK重排的临床研究. 赣南医学院学报. 2022(10): 1003-1009+1035 . 百度学术
7. 钟炜祥,韦晰凤. 应用不平衡法检测赣南地区原发性肺腺癌ALK融合突变. 肿瘤防治研究. 2021(12): 1066-1070 . 百度学术
其他类型引用(2)
-

计量
- 文章访问数: 3187
- HTML全文浏览量: 1108
- PDF下载量: 136
- 被引次数: 9